CHINA TOPIX

11/22/2024 02:19:05 am

Make CT Your Homepage

Acute Lymphoblastic Leukemia

Amgen Announces BLINCYTO A Successful Drug For Leukemia

Amgen Announces BLINCYTO A Successful Drug For Leukemia In Phase 2 Trial

BLINCYTO, a drug for relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia, was found to be a great success in phase 2 trials, announced Amgen on Thursday, July 16.

Acute Lymphoblastic Leukemia Cells

FDA Dubs Personalized Immunotherapy for Leukemia as “Breakthrough”

After recording 89 percent of leukemia patients going into complete remission during initial trials, the U.S. Food and Drug Administration (FDA) put an experimental immunotherapy agent on the express train to market approval.

Real Time Analytics